<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114212</article-id><article-id pub-id-type="publisher-id">ACM-41499</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_18385216.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  弥漫性肺泡出血在系统性红斑狼疮和ANCA相关性血管炎的临床特征比较分析
  Comparative Analysis of the Clinical Features of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus and ANCA-Related Vasculitis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卢</surname><given-names>祥云</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>柯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>温</surname><given-names>大蔚</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>辛</surname><given-names>苗苗</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>梁</surname><given-names>宏达</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院风湿免疫科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1482</fpage><lpage>1489</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨弥漫性肺泡出血(DAH)患者在系统性红斑狼疮(SLE)和ANCA相关性血管炎(AAV)的临床特征和预后比较分析。方法：选取2012年1月至2019年12月就诊于青岛大学附属医院的SLE-DAH和AAV-DAH的病例，对两组患者的临床特征进行回顾性对比分析。结果：DAH患者共计42例，其中SLE-DAH组患者22例，AAV-DAH组患者20例，两组患者在性别(χ
   <sup>2</sup> = 23.100, P = 0.000)、年龄(t = −2.625, P = 0.015)、原发病确诊到DAH病程时长(z = −2.051, P = 0.040)、C3下降值(z = −5.001, P = 0.000)、血WBC计数(z = −2.166, P = 0.030)、抗SSA/SSB抗体(χ
   <sup>2</sup> = 12.099, P = 0.001)、抗心磷脂抗体测定(χ
   <sup>2</sup> = 8.984, P = 0.003)、Coomb’s试验(χ
   <sup>2</sup> = 8.984, P = 0.003)、胸腔积液(χ
   <sup>2</sup> = 4.582, P = 0.032)以及多浆膜腔积液(χ
   <sup>2</sup> = 6.018, P = 0.014)，比较有统计学意义(P &lt; 0.05)；咯血或痰中带血、呼吸困难、发热、肺部听诊啰音、肺部感染、低蛋白血症、PLT计数、24小时尿蛋白升高值、动脉血氧分压值无统计学意义(P &gt; 0.05)。SLEDAI评分为：12~27，平均17.91 &#177; 4.40，伯明翰系统性血管炎活动评分(BVAS)为：15~36，平均21.30 &#177; 5.71。两组患者使用大剂量激素冲击治疗、环磷酰胺、吗替麦考酚酯、机械通气、血浆置换等治疗，死亡率皆小于50%，但患者死亡率比较无统计学意义(P &gt; 0.05)。结论：弥漫性肺泡出血是系统性红斑狼疮和ANCA相关性血管炎都可以出现的一种危重并发症，但是在两种不同的自身免疫性疾病之间又有不完全一致的表现形式。在临床诊疗过程中，若患者存在咯血、呼吸困难、血红蛋白急骤下降等表现时应考虑弥漫性肺泡出血可能，也要考虑继发于自身免疫病的情况。早期诊断、早期治疗对患者的生存率至关重要。
    Objective: To investigate the clinical features and prognosis of diffuse alveolar hemorrhage (DAH) in patients with systemic lupus erythematosus (SLE) and ANCA-related vasculitis (AAV). Methods: The SLE-DAH and AAV-DAH cases in the Affiliated Hospital of Qingdao University from January 2012 to December 2019 were selected, and the clinical diagnosis and treatment characteristics of the two groups of patients were retrospectively compared and analyzed. Results: There were 42 patients with DAH, including 22 patients in the SLE-DAH group and 20 patients in the AAV-DAH group. In the two groups of patients, gender (χ2 = 23.100, P = 0.000), age (t = −2.625, P = 0.015), the length of time from the diagnosis of the primary disease to the course of DAH (z = −2.051, P = 0.040), C3 decline (z = −5.001, P = 0.000), blood WBC count (z = −2.166, P = 0.030), anti-SSA/SSB antibodies (χ
   <sup>2</sup> = 12.099, P = 0.001), anti-cardiolipin antibody determination (χ2 = 8.984, P = 0.003), Coomb’s test (χ
   <sup>2</sup> = 8.984, P = 0.003), pleural effusion (χ
   <sup>2</sup> = 4.582, P = 0.032), and more Serous effusion (χ
   <sup>2</sup> = 6.018, P = 0.014) are statistically significant (P &lt; 0.05); Hemoptysis or blood in sputum, dyspnea, fever, pulmonary auscultation rales, lung infection, hypoalbuminemia, PLT count, 24-hour urine protein elevation, and arterial partial pressure of oxygen were not statistically significant (P &gt; 0.05). The SLEDAI score was 12~27, with an average of 17.91 &#177; 4.40, and the Birmingham Systemic Vasculitis Activity Score (BVAS) was 15~36, with an average of 21.30 &#177; 5.71. The two groups of patients were treated with high-dose glucocorticoid shock therapy, cyclophosphamide, mycophenolate mofetil, mechanical ventilation, plasma exchange and other treatments. The mortality rate was less than 50%, but the mortality rate of the patients was not statistically significant (P &gt; 0.05). Conclusion: Diffuse alveolar hemorrhage is a critical complication that can occur in both systemic lupus erythematosus and ANCA-associated vasculitis, but there are incompletely consistent manifestations between two different autoimmune diseases. In the course of clinical diagnosis and treatment, if the patient has hemoptysis, dyspnea, sudden drop in hemoglobin, etc., the possibility of diffuse alveolar hemorrhage should be considered, and the situation secondary to autoimmune disease should also be considered. Early diagnosis and early treatment are critical to the survival rate of patients. 
   
   
    
  
 
</p></abstract><kwd-group><kwd>弥漫性肺泡出血，系统性红斑狼疮，ANCA相关性血管炎，诊疗, Diffuse Alveolar Hemorrhage</kwd><kwd> Systemic Lupus Erythematosus</kwd><kwd> ANCA-Related Vasculitis</kwd><kwd> Diagnosis and Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨弥漫性肺泡出血(DAH)患者在系统性红斑狼疮(SLE)和ANCA相关性血管炎(AAV)的临床特征和预后比较分析。方法：选取2012年1月至2019年12月就诊于青岛大学附属医院的SLE-DAH和AAV-DAH的病例，对两组患者的临床特征进行回顾性对比分析。结果：DAH患者共计42例，其中SLE-DAH组患者22例，AAV-DAH组患者20例，两组患者在性别(χ2 = 23.100, P = 0.000)、年龄(t = −2.625, P = 0.015)、原发病确诊到DAH病程时长(z = −2.051, P = 0.040)、C3下降值(z = −5.001, P = 0.000)、血WBC计数(z = −2.166, P = 0.030)、抗SSA/SSB抗体(χ2 = 12.099, P = 0.001)、抗心磷脂抗体测定(χ2 = 8.984, P = 0.003)、Coomb’s试验(χ2 = 8.984, P = 0.003)、胸腔积液(χ2 = 4.582, P = 0.032)以及多浆膜腔积液(χ2 = 6.018, P = 0.014)，比较有统计学意义(P &lt; 0.05)；咯血或痰中带血、呼吸困难、发热、肺部听诊啰音、肺部感染、低蛋白血症、PLT计数、24小时尿蛋白升高值、动脉血氧分压值无统计学意义(P &gt; 0.05)。SLEDAI评分为：12~27，平均17.91 &#177; 4.40，伯明翰系统性血管炎活动评分(BVAS)为：15~36，平均21.30 &#177; 5.71。两组患者使用大剂量激素冲击治疗、环磷酰胺、吗替麦考酚酯、机械通气、血浆置换等治疗，死亡率皆小于50%，但患者死亡率比较无统计学意义(P &gt; 0.05)。结论：弥漫性肺泡出血是系统性红斑狼疮和ANCA相关性血管炎都可以出现的一种危重并发症，但是在两种不同的自身免疫性疾病之间又有不完全一致的表现形式。在临床诊疗过程中，若患者存在咯血、呼吸困难、血红蛋白急骤下降等表现时应考虑弥漫性肺泡出血可能，也要考虑继发于自身免疫病的情况。早期诊断、早期治疗对患者的生存率至关重要。</p></sec><sec id="s2"><title>关键词</title><p>弥漫性肺泡出血，系统性红斑狼疮，ANCA相关性血管炎，诊疗</p></sec><sec id="s3"><title>Comparative Analysis of the Clinical Features of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus and ANCA-Related Vasculitis</title><p>Xiangyun Lu<sup>1*</sup>, Ke Ma<sup>1</sup>, Dawei Wen<sup>2</sup>, Miaomiao Xin<sup>2</sup>, Hongda Liang<sup>2#</sup></p><p><sup>1</sup>Medical Department, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/5-1572090x5_hanspub.png" /></p><p>Received: Mar. 6<sup>th</sup>, 2021; accepted: Mar. 30<sup>th</sup>, 2021; published: Apr. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/5-1572090x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the clinical features and prognosis of diffuse alveolar hemorrhage (DAH) in patients with systemic lupus erythematosus (SLE) and ANCA-related vasculitis (AAV). Methods: The SLE-DAH and AAV-DAH cases in the Affiliated Hospital of Qingdao University from January 2012 to December 2019 were selected, and the clinical diagnosis and treatment characteristics of the two groups of patients were retrospectively compared and analyzed. Results: There were 42 patients with DAH, including 22 patients in the SLE-DAH group and 20 patients in the AAV-DAH group. In the two groups of patients, gender (χ2 = 23.100, P = 0.000), age (t = −2.625, P = 0.015), the length of time from the diagnosis of the primary disease to the course of DAH (z = −2.051, P = 0.040), C3 decline (z = −5.001, P = 0.000), blood WBC count (z = −2.166, P = 0.030), anti-SSA/SSB antibodies (χ2 = 12.099, P = 0.001), anti-cardiolipin antibody determination (χ2 = 8.984, P = 0.003), Coomb’s test (χ2 = 8.984, P = 0.003), pleural effusion (χ2 = 4.582, P = 0.032), and more Serous effusion (χ2 = 6.018, P = 0.014) are statistically significant (P &lt; 0.05); Hemoptysis or blood in sputum, dyspnea, fever, pulmonary auscultation rales, lung infection, hypoalbuminemia, PLT count, 24-hour urine protein elevation, and arterial partial pressure of oxygen were not statistically significant (P &gt; 0.05). The SLEDAI score was 12~27, with an average of 17.91 &#177; 4.40, and the Birmingham Systemic Vasculitis Activity Score (BVAS) was 15~36, with an average of 21.30 &#177; 5.71. The two groups of patients were treated with high-dose glucocorticoid shock therapy, cyclophosphamide, mycophenolate mofetil, mechanical ventilation, plasma exchange and other treatments. The mortality rate was less than 50%, but the mortality rate of the patients was not statistically significant (P &gt; 0.05). Conclusion: Diffuse alveolar hemorrhage is a critical complication that can occur in both systemic lupus erythematosus and ANCA-associated vasculitis, but there are incompletely consistent manifestations between two different autoimmune diseases. In the course of clinical diagnosis and treatment, if the patient has hemoptysis, dyspnea, sudden drop in hemoglobin, etc., the possibility of diffuse alveolar hemorrhage should be considered, and the situation secondary to autoimmune disease should also be considered. Early diagnosis and early treatment are critical to the survival rate of patients.</p><p>Keywords:Diffuse Alveolar Hemorrhage, Systemic Lupus Erythematosus, ANCA-Related Vasculitis, Diagnosis and Treatment</p><disp-formula id="hanspub.41499-formula19"><graphic xlink:href="//html.hanspub.org/file/5-1572090x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-1572090x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-1572090x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>弥漫性肺泡出血(Diffuse alveolar hemorrhage, DAH)是以咯血、呼吸困难、进行性Hb下降以及影像学显示双侧弥漫浸润影等为特征性表现的一种罕见疾病，在风湿病中，常见于系统性红斑狼疮(Systemic lupus erythematosus, SLE)以及ANCA相关性血管炎(ANCA-related vasculitis, AAV)等自身免疫性疾病患者当中 [<xref ref-type="bibr" rid="hanspub.41499-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref3">3</xref>]。虽然DAH较为罕见，但是一旦出现将危及患者生命，目前国际上尚无规范统一的诊疗方案，患者的早期诊断，积极治疗可能会降低患者的死亡率。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 纳入标准与排除标准</title><p>纳入本研究的SLE患者符合1997年美国风湿病学会(ACR)关于SLE的诊断标准 [<xref ref-type="bibr" rid="hanspub.41499-ref4">4</xref>]，AAV患者符合1993年Chapel Hill共识会议上系统性血管炎分类标准 [<xref ref-type="bibr" rid="hanspub.41499-ref5">5</xref>]。目前在国际上DAH的较为统一的诊断标准(至少符合以下4条诊断标准中的3条)：1) 胸部症状：咳嗽，咯血，呼吸困难或低氧血症；2) 在无明确出血源的情况下，Hb下降 ≥ 1.5 g/L；3) 胸部影像学显示新的浸润；4、支气管肺泡灌洗液(BAL)可见含含铁血黄素的巨噬细胞或为血性。同时符合SLE (或AAV)和DAH的患者分别被诊断为SLE-DAH和AAV-DAH。需除外严重凝血障碍(国际标准化比率 &gt; 3.5)，支气管扩张，急性肺水肿或肺栓塞等疾病 [<xref ref-type="bibr" rid="hanspub.41499-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref8">8</xref>]。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>收集2012年1月至2019年12月就诊于青岛大学附属医院且符合上述诊断标准的患者资料，对SLE-DAH组和AAV-DAH组之间的临床资料进行对比研究，其临床资料包括患者的一般资料、临床表现、实验室等辅助检查、治疗方案及预后等。</p></sec><sec id="s6_3"><title>2.3. 统计学分析</title><p>采用SPSS 25.0软件进行统计学分析。计量资料用(x &#177; s)表示，两组资料比较采用秩和检验；计数资料采用百分比(%)表示，两组资料比较采用卡方检验及Fisher精确概率法。P &lt; 0.05有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果分析</title><sec id="s7_1"><title>3.1. DAH患者的一般情况</title><p>DAH患者共42例，其中，22例系统性红斑狼疮合并肺泡出血患者中，全部为女性患者(100%)；20例ANCA相关性血管炎合并弥漫性肺泡出血患者中，女性患者为6例(30%)，其年龄在16~84岁，平均年龄为58.05 &#177; 20.48岁，而前者年龄在16~76岁，平均年龄为38.14 &#177; 16.80岁，两组患者性别(χ2 = 23.100, P = 0.000)及年龄(t = −2.625, P = 0.015)比较有统计学意义(P &lt; 0.05)。见表1。SLE/AAV确诊至DAH首发症状出现时间：SLE-DAH组平均值为14.00 &#177; 24.45月，AAV-DAH组平均值为2.15 &#177; 4.46月。SLE组原发病到出现DAH的时间要长于AAV-DAH组，且两研究组原发病至DAH时长(z = −2.051, P = 0.040)之间比较有统计学意义(P &lt; 0.05)。见表1。系统性红斑狼疮疾病活动度评分(Systemic lupus erythematosus disease activity index, SLEDAI)评分为：12~27，平均17.91 &#177; 4.40，伯明翰系统性血管炎活动评分(Birming-ham vasculitis activity score, BVAS)为：15~36，平均21.30 &#177; 5.71。</p></sec><sec id="s7_2"><title>3.2. DAH患者的临床特点</title><p>SLE-DAH组患者出现DAH时的首发症状为：呼吸困难11例(50.00%)，咯血或痰中带血8例(36.36%)，发热3例(13.64%)。常见临床表现：贫血22例(100%)，咯血或痰中带血18例(81.82%)，呼吸困难16例(72.73%)，发热10例(45.45%)，查体可闻及肺部啰音为18例(81.82%)，肺部感染17例(77.27%)，低白蛋白血症20例(90.91%)。AAV-DAH组患者出现DAH时首发症状为：咯血或痰中带血例11例(55.00%)，发热5例(25.00%)、呼吸困难4例(20.00%)。常见临床表现：贫血20例(100%)，咯血或痰中带血16例(80.00%)，呼吸困难例15 (75.00%)，发热12例(60.00%)，查体可闻及肺部啰音为16例(80.00%)，肺部感染16例(80.00%)，低白蛋白血症17例(85.00%)。本次研究中，两组患者症状比较，咯血或痰中带血、呼吸困难、发热、肺部听诊啰音、肺部感染、低蛋白血症无统计学意义(P &gt; 0.05)。见表2。</p></sec><sec id="s7_3"><title>3.3. 实验室检查</title><p>SLE-DAH组患者中21例C3降低(95.45%)，24小时尿蛋白定量 &gt; 0.5 g/L为13例(59.09%)，其中24小时尿蛋白定量 &gt; 3 g/L者为3例(13.64%)，PLT计数减少到少于100*10^9/L为12例(54.55%)，动脉氧分压降低为11例(50.00%)；</p><p>AAV-DAH组患者中6例C3降低(30.00%)，24小时尿蛋白定量 &gt; 0.5 g/L者为12例(60.00%)，24小时尿蛋白定量 &gt; 3 g/L者为2例(10.00%)，PLT计数减少为6例(30.00%)，动脉氧分压降低为9例(45.00%)；两组患者之间C3下降值(z = −5.001, P = 0.000)、血WBC计数(z = −2.166, P = 0.030)有统计学意义(P &lt; 0.05)但两组患者PLT计数、24小时尿蛋白升高值、动脉血氧分压降低之间无明显统计学意义(P &gt; 0.05)。见表1。</p><p>对于免疫学指标，在SLE-DAH患者中，抗核抗体全部阳性(100%)、抗ds’DNA阳性为14例(27.27%)、抗Sm抗体阳性为6例(%)、Coomb’s试验4例(18.18%)、抗心磷脂抗体为5例(22.73%)、抗SSA/SSB抗体阳性15例(68.18%)。AAV-DAH组患者的ANA阳性为9例(45.00%)，抗SSA/SSB抗体阳性者为3例(15.00%)，抗ds’DNA抗体、抗Sm抗体、Coomb’s试验、抗心磷脂抗体无阳性病例。两组患者比较，抗SSA/SSB抗体(χ2 = 12.099, P = 0.001)、抗心磷脂抗体测定(χ2 = 8.984, P = 0.003)、Coomb’s试验(χ2 = 8.984, P = 0.003)有统计学意义(P &lt; 0.05)。</p></sec><sec id="s7_4"><title>3.4. 影像学检查</title><p>所有患者胸部CT示双肺内可见新发的双侧散在或弥漫浸润影，16例(72.73%) SLE-DAH患者存在胸腔积液，多浆膜腔积液患者为13例(59.09%)。AAV-DAH组存在胸腔积液的患者为8例(40.00%)，多浆膜腔积液4例(20.00%)。两组患者胸腔积液(χ2 = 4.582, P = 0.032)以及多浆膜腔积液(χ2 = 6.018, P = 0.014)比较都具有统计学意义(P &lt; 0.05)。见表2。</p></sec><sec id="s7_5"><title>3.5. 治疗</title><p>所有患者应用不同剂量的激素进行自身免疫性疾病合并DAH的治疗，SLE-DAH组患者中，大剂量激素冲击治疗17例(77.27%)，其中共有5例(22.73%)重复行激素冲击治疗，单人激素冲击量 ≥ 3 g为8例(36.36%)；其余5例(22.73%)患者应用中等剂量激素，且合用免疫抑制剂。13例(59.09%)应用复方环磷酰胺，应用吗替麦考酚酯者4例(18.18%)，15例(68.18%)给予丙种球蛋白治疗，机械通气9例(40.91%)，7例(31.82%)行血浆置换治疗。AAV-DAH组患者中，大剂量激素冲击治疗10例(50.00%)，其中6例(30.00%)患者重复大量激素冲击治疗，单人激素冲击量 ≥ 3 g为8例(40.00%)；应用CTX 11例(55.00%)，吗替麦考酚酯2例(10.00%)，血浆置换9例(45.00%)，7例(35.00%)患者应用丙种球蛋白治疗及机械通气。两组患者全部(100.00%)应用抗生素预防或抗感染治疗。</p><p>本研究中，两组患者比较，使用丙种球蛋白者有统计学意义(P &lt; 0.05)；使用大剂量激素冲击治疗、环磷酰胺、吗替麦考酚酯、机械通气、血浆置换的两组患者比较，没有统计学意义(P &gt; 0.05)。单人冲击2次及以上、单人次总冲击量 ≥ 3 g无统计学意义(P &gt; 0.05)。</p></sec><sec id="s7_6"><title>3.6. 转归</title><p>SLE-DAH组患者死亡9例(40.91%)，AAV-DAH组死亡7例(35.00%)，两组患者死亡率比较无统计学意义(P &gt; 0.05)。</p></sec><sec id="s7_7"><title>3.7. 随访</title><p>出院病例全部回我院随访。在此特别强调的是分别有1例确诊AAV-DAH 的患者和1例确诊为SLE-DAH的患者，于出院后因慢性肾功能不全尿毒症期而于我院肾移植科行肾移植治疗，术后恢复可，后一直服用小剂量激素及免疫抑制剂治疗。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The comparison of observation indexes between SLE-DAH group and AAV-DAH grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >年龄(岁)</th><th align="center" valign="middle" >原发病确诊-DAH 时长</th><th align="center" valign="middle" >PLT计数(*10^9)</th><th align="center" valign="middle" >血WBC计数(*10^9)</th><th align="center" valign="middle" >C3 (g/l)</th><th align="center" valign="middle" >动脉氧分压</th><th align="center" valign="middle" >24 h尿蛋白(g)</th></tr></thead><tr><td align="center" valign="middle" >SLE-DAH组</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >38.14 &#177; 16.80</td><td align="center" valign="middle" >14.00 &#177; 24.45</td><td align="center" valign="middle" >118.77 &#177; 82.00</td><td align="center" valign="middle" >7.38 &#177; 4.86</td><td align="center" valign="middle" >0.42 &#177; 0.25</td><td align="center" valign="middle" >65.04 &#177; 19.21</td><td align="center" valign="middle" >1.39 &#177; 1.84</td></tr><tr><td align="center" valign="middle" >AAV-DAH组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >58.05 &#177; 20.48</td><td align="center" valign="middle" >2.15 &#177; 4.46</td><td align="center" valign="middle" >298.73 &#177; 138.22</td><td align="center" valign="middle" >9.26 &#177; 2.81</td><td align="center" valign="middle" >1.09 &#177; 0.32</td><td align="center" valign="middle" >71.46 &#177; 22.65</td><td align="center" valign="middle" >1.20 &#177; 1.34</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >0.040</td><td align="center" valign="middle" >0.054</td><td align="center" valign="middle" >0.030</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.262</td><td align="center" valign="middle" >0.870</td></tr></tbody></table></table-wrap><p>表1. SLE-DAH组和AAV-DAH组患者观察指标比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The comparison of symptoms and signs between SLE-DAH group and AAV-DAH grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >咯血或痰中带血</th><th align="center" valign="middle" >呼吸困难</th><th align="center" valign="middle" >发热</th><th align="center" valign="middle" >听诊肺部啰音</th><th align="center" valign="middle" >胸腔积液</th><th align="center" valign="middle" >多浆膜腔积液</th><th align="center" valign="middle" >肺部感染</th><th align="center" valign="middle" >低蛋白血症</th></tr></thead><tr><td align="center" valign="middle" >SLE-DAH组</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >AAV-DAH组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >17</td></tr><tr><td align="center" valign="middle"  colspan="2"  >P值</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >0.867</td><td align="center" valign="middle" >0.346</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >0.032</td><td align="center" valign="middle" >0.014</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >0.656</td></tr></tbody></table></table-wrap><p>表2. SLE-DAH组和AAV-DAH组症状体征比较</p></sec></sec><sec id="s8"><title>4. 讨论及分析</title><p>本研究对近8年就诊于我院的SLE-DAH和AAV-DAH患者临床诊疗特征进行回顾性研究分析，两研究组之间的临床诊疗特征比较为本次研究的主要目的。</p><p>一项来自中国的回顾性研究表明，SLE-DAH的患者年龄介于9岁~62岁之间，25/29名患者为女性 [<xref ref-type="bibr" rid="hanspub.41499-ref6">6</xref>]，而AAV-DAH组患者年龄偏大，且更有可能是男性 [<xref ref-type="bibr" rid="hanspub.41499-ref9">9</xref>]。在本研究中，SLE-DAH组全部为女性患者，年龄介于16~76岁，AAV-DAH组患者年龄在16~84岁之间，其中14例为男性患者，两研究组之间比较，SLE-DAH组较AAV-DAH组患者更易出现在中青年女性，这可能与系统性红斑狼疮在育龄期女性发病率高有关，且SLE-DAH组患者从原发病到出现DAH首发症状的时间与AAV-DAH组患者相比是有差异的，前者较后者时间长且具有统计学意义。</p><p>咯血，急性Hb下降和胸部影像学出现新的浸润组成了DAH的经典三联征 [<xref ref-type="bibr" rid="hanspub.41499-ref1">1</xref>]。DAH的临床表多种多样，但是约1/3的患者最初可能不会出现咯血症状 [<xref ref-type="bibr" rid="hanspub.41499-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref10">10</xref>]，这与本研究类似。DAH的及时识别可能是取得更好预后的重要一步，呼吸困难、低氧血症，咯血、Hb值下降及弥漫性肺泡或间质浸润等临床表现的出现可提示DAH，特别是在疾病活动的患者中 [<xref ref-type="bibr" rid="hanspub.41499-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref12">12</xref>]。本研究中，患者发病时全部出现贫血及Hb值的下降，部分患者出现咯血或痰中带血、呼吸困难、发热等临床症状，且全部病例排除肺结核等疾病。两组患者症状比较，咯血或痰中带血、呼吸困难、发热、肺部听诊啰音、肺部感染、低蛋白血症无统计学意义。DAH患者的影像学表现，特别是高分辨率计算机断层扫描，可支持DAH的诊断 [<xref ref-type="bibr" rid="hanspub.41499-ref10">10</xref>]。本研究中所有患者胸部CT可见新发的双侧散在或弥漫浸润影，部分患者可见胸腔积液甚至多浆膜腔积液。两对比组之间，SLE-DAH组胸腔积液及多浆膜腔积液例数均多于AAV-DAH组且有统计学意义，这说明SLE-DAH患者较AAV-DAH患者更易合并浆膜腔积液，也可能与原发病相关。。</p><p>之前的一些研究对DAH定义很模糊，在一项欧洲血管炎研究小组针对387例ANCA相关性血管炎患者的回顾性分析中，他们通过咯血和/或肺部浸润诊断DAH [<xref ref-type="bibr" rid="hanspub.41499-ref13">13</xref>]。支气管肺泡灌洗(BAL)检查可用于DAH患者的确诊，经支气管镜肺活检(TBLB)或手术活检也可诊断DAH，但是活检的诊断率仍然不理想，而手术的风险往往大于益处 [<xref ref-type="bibr" rid="hanspub.41499-ref10">10</xref>]。在本研究的两组患者中，大部分患者有肺部感染征象。DAH与肺部感染加重之间难于鉴别，虽然BAL检查可以鉴别肺部感染，但是因为检查本身有侵袭性且有院内感染的风险，所以BAL检查也有一定的局限性 [<xref ref-type="bibr" rid="hanspub.41499-ref6">6</xref>]。</p><p>PLT计数减少和C3低下可能是DAH的独立危险因素 [<xref ref-type="bibr" rid="hanspub.41499-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref14">14</xref>]。在两组化验指标中，SLE-DAH组患者更易消耗补体，且更易累及血液系统，可能与原发疾病相关；虽然在本研究中，PLT计数减少在两组之间比较没有统计学意义，但并不能就此说明PLT计数减少和DAH之间无关。SLE-DAH组可能与抗SSA/SSB阳性的继发干燥综合征相关，目前仅一篇文献提及抗SSA抗体可能是SLE患者DAH的潜在预测指标[<xref ref-type="bibr" rid="hanspub.41499-ref8">8</xref>]。抗磷脂抗体也可能与DAH的发生相关联 [<xref ref-type="bibr" rid="hanspub.41499-ref13">13</xref>]，一项来自韩国的研究表明，SLE疾病活动指数高(SLEDAI &gt; 10)是DAH发展的独立危险因素 [<xref ref-type="bibr" rid="hanspub.41499-ref15">15</xref>]，中国的一项研究中表明，DAH的发展和ANCA相关性血管炎活动之间存在一定的关系 [<xref ref-type="bibr" rid="hanspub.41499-ref16">16</xref>]，在此次研究中，SLE疾病活动指数(SLEDAI)评分和伯明翰系统性血管炎活动评分(BVAS)普遍较高，这表明疾病的高活动度可能与DAH的发生相关。</p><p>目前DAH在SLE中的治疗与AAV-DAH相似，DAH患者应该尽早应用糖皮质激素和免疫抑制剂联合诱导治疗 [<xref ref-type="bibr" rid="hanspub.41499-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref18">18</xref>]，血浆置换可用于治疗对大剂量激素冲击治疗和环磷酰胺治疗反应差的患者，利妥昔单抗(RTX)也可用于治疗DAH，其主要作用机制是CD20 B淋巴细胞耗竭相关 [<xref ref-type="bibr" rid="hanspub.41499-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref19">19</xref>]。机械通气是DAH呼吸道管理的重要方面 [<xref ref-type="bibr" rid="hanspub.41499-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref20">20</xref>]，在一些病例报告中还描述了其他治疗方案，包括活化因子VII疗法以及体外膜氧合(ECMO)等，但是上述两种治疗方法的疗效并未明确 [<xref ref-type="bibr" rid="hanspub.41499-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref23">23</xref>]。吗替麦考酚酯联合糖皮质激素也可用于DAH的治疗 [<xref ref-type="bibr" rid="hanspub.41499-ref9">9</xref>]。本研究中，两组患者比较，使用大剂量激素冲击治疗、环磷酰胺、吗替麦考酚酯、机械通气、血浆置换的两组患者比较，没有统计学意义(P &gt; 0.05)。单人冲击2次及以上、单人次总冲击量 ≥ 3 g也没有统计学意义(P &gt; 0.05)。</p><p>尽管近期DAH患者的死亡率有所降低，但是各报道中死亡率仍然在0%~92%之间(平均约50%) [<xref ref-type="bibr" rid="hanspub.41499-ref21">21</xref>]。本研究中两组患者的死亡率均低于平均水平，SLE-DAH组和AAV-DAH组的死亡率分别为40.91%和35.00%，但是两组患者死亡率无统计学差异。值得强调的是有研究表明，DAH患者的肺部感染及感染导致的死亡率较高，所以在DAH发病的早期就应该使用广谱抗生素进行积极的抗感染治疗 [<xref ref-type="bibr" rid="hanspub.41499-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.41499-ref24">24</xref>]，在本研究中，所有病例积极应用抗生素抗感染治疗。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，免疫系统疾病作为弥漫性肺泡出血的重要元凶之一，尤其在系统性红斑狼疮和ANCA相关性血管炎中是不可忽视的。弥漫性肺泡出血是一种少见且危险的并发症，早期诊断，积极治疗可能会降低其死亡率，支气管镜检查及支气管肺泡灌洗(BAL)检查可用于确诊弥漫性肺泡出血，但是需要经过专业临床医师依据患者具体病情权衡利弊后决定是否采用。</p></sec><sec id="s10"><title>文章引用</title><p>卢祥云,马 柯,温大蔚,辛苗苗,梁宏达. 弥漫性肺泡出血在系统性红斑狼疮和ANCA相关性血管炎的临床特征比较分析Comparative Analysis of the Clinical Features of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus and ANCA-Related Vasculitis[J]. 临床医学进展, 2021, 11(04): 1482-1489. https://doi.org/10.12677/ACM.2021.114212</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41499-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Abdalla, A.O., Jaafar, A.K., Akella, P.M. and Taha, M. (2018) A Fatal Case of Diffuse Alveolar Hemorrhage as the Initial Presentation of Systemic Lupus Erythematosus: A Case Report and Literature Review. Respiratory Medicine Case Reports, 24, 55-57. &lt;br&gt;https://doi.org/10.1016/j.rmcr.2018.04.006</mixed-citation></ref><ref id="hanspub.41499-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Andrade, C., Mendonca, T., Farinha, F., Correia, J., Marinho, A., Almeida, I., et al. (2015) Alveolar Hemorrhage in Systemic Lupus Erythematosus: A Cohort Review. Lupus, 25, 75-80. &lt;br&gt;https://doi.org/10.1177/0961203315605365</mixed-citation></ref><ref id="hanspub.41499-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Polok, K., Włudarczyk, A. and Szczeklik, W. (2019) Clinical Profile of Patients with Systemic Autoimmune Diseases Treated in the Intensive Care Unit Who Developed Diffuse Alveolar Haemorrhage—An Observational Retrospective Cohort Study. Anaesthesiology Intensive Therapy, 51, 96-101. &lt;br&gt;https://doi.org/10.5114/ait.2019.86164</mixed-citation></ref><ref id="hanspub.41499-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Doria, A., Zen, M., Canova, M., Bettio, S., Bassi, N., Nalotto, L., et al. (2010) SLE Diagnosis and Treatment: When Early Is Early. Autoimmunity Reviews, 10, 55-60. &lt;br&gt;https://doi.org/10.1016/j.autrev.2010.08.014</mixed-citation></ref><ref id="hanspub.41499-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Jennette, J.C., Falk, R.J., Andrassy, K., Bacon, P.A., Churg, J., Gross, W.L., et al. (1994) Nomencalture of Systemic Vasculitides: The Proposal of an International Consensus Conference. Arthritis &amp; Rheumatism, 37, 187-192.  
&lt;br&gt;https://doi.org/10.1002/art.1780370206</mixed-citation></ref><ref id="hanspub.41499-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Shen, M., Zeng, X., Tian, X., Zhang, F., Zeng, X., Zhang, X., et al. (2010) Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: A Retrospective Study in China. Lupus, 19, 1326-1330.  
&lt;br&gt;https://doi.org/10.1177/0961203310373106</mixed-citation></ref><ref id="hanspub.41499-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">林毅, 郑文洁, 张烜, 张奉春, 唐福林. ANCA相关性小血管炎合并弥漫性肺泡出血12例分析[J]. 北京医学, 2008, 30(9): 15-17.</mixed-citation></ref><ref id="hanspub.41499-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Y., Zhou, C., Zhao, J., Wang, Q., Xu, D., Zhang, S., et al. (2020) Systemic Lupus Erythematosus-Associated Diffuse Alveolar Hemorrhage: A Single-Center, Matched Case-Control Study in China. Lupus, 29, 795-803.  
&lt;br&gt;https://doi.org/10.1177/0961203320920715</mixed-citation></ref><ref id="hanspub.41499-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lara, A.R. and Schwarz, M.I. (2010) Diffuse Alveolar Hemorrhage. Chest, 137, 1164-1171.  
&lt;br&gt;https://doi.org/10.1378/chest.08-2084</mixed-citation></ref><ref id="hanspub.41499-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Krause, M.L., Cartin-Ceba, R., Specks, U. and Peikert, T. (2012) Update on Diffuse Alveolar Hemorrhage and Pulmonary Vasculitis. Immunology &amp; Allergy Clinics of North America, 32, 587-600.  
&lt;br&gt;https://doi.org/10.1016/j.iac.2012.08.001</mixed-citation></ref><ref id="hanspub.41499-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Araujo, D., Borba, E., Silva, C., Campos, L.M.A., Pereira, R.M.R., Bonfa, E., et al. (2012) Alveolar Hemorrhage: Distinct Features of Juvenile and Adult Onset Systemic Lupus Erythematosus. Lupus, 21, 872-877.  
&lt;br&gt;https://doi.org/10.1177/0961203312441047</mixed-citation></ref><ref id="hanspub.41499-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Menna Barreto, I.G., Gomes de Araujo, I.S. and de Araujo, D.B. (2016) Alveolar Hemorrhage as the Initial Presentation of Systemic Lupus Erythematosus. Reumatologia, 54, 264-266. &lt;br&gt;https://doi.org/10.5114/reum.2016.63668</mixed-citation></ref><ref id="hanspub.41499-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Robert, T., Romulo, C. and Brian, W.A. (2017) Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Histopathologic Features and Clinical Correlations. Case Reports in Pathology, 2017, Article ID: 1936282.  
&lt;br&gt;https://doi.org/10.1155/2017/1936282</mixed-citation></ref><ref id="hanspub.41499-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kovács, L., Simon, J., Kovács, A., Pócsik, A., Boros, I., Iványi, B., et al. (2002) Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus. Orvosi Hetilap, 141, 179-183.</mixed-citation></ref><ref id="hanspub.41499-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kwok, S.K., Moon, S.J., Ju, J.H., Park, K.-S., Kim, W.-U., Cho, C.S., et al. (2011) Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Risk Factors and Clinical Outcome: Results from Affiliated Hospitals of Catholic University of Korea. Lupus, 20, 102-107. &lt;br&gt;https://doi.org/10.1177/0961203310381511</mixed-citation></ref><ref id="hanspub.41499-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Y., Zheng, W., Tian, X., Zhang, X., Zhang, F. and Dong, Y. (2009) Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Complicated with Diffuse Alveolar Hemorrhage: A Study of 12 Cases. Journal of Clinical Rheumatology, 15, 341-344. &lt;br&gt;https://doi.org/10.1097/RHU.0b013e3181b59581</mixed-citation></ref><ref id="hanspub.41499-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Cordier, J. and Cottin, V. (2011) Alveolar Hemorrhage in Vasculitis: Primary and Secondary. Seminars in Respiratory and Critical Care Medicine, 32, 310-321. &lt;br&gt;https://doi.org/10.1055/s-0031-1279827</mixed-citation></ref><ref id="hanspub.41499-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mahmoud, G.A., Gheith, R.E., Kamel, M.M. and Soliman, R.A. (2011) Alveolar Hemorrhage in Systemic Lupus Erythematosus: An Overview. The Egyptian Rheumatologist, 33, 1-11. &lt;br&gt;https://doi.org/10.1016/j.ejr.2010.02.001</mixed-citation></ref><ref id="hanspub.41499-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cartin-Ceba, R., Diaz-Caballero, L., Al-Qadi, M.O., Tryfon, S., Fervenza, F.C., Ytterberg, S.R., et al. (2016) Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis &amp; Rheumatology, 68, 1467-1476. &lt;br&gt;https://doi.org/10.1002/art.39562</mixed-citation></ref><ref id="hanspub.41499-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Martinez-Martinez, M. and Abud-Mendoza, C. (2011) Predictors of Mortality in Diffuse Alveolar Haemorrhage Associated with Systemic Lupus Erythematosus. Lupus, 20, 568-574. &lt;br&gt;https://doi.org/10.1177/0961203310392430</mixed-citation></ref><ref id="hanspub.41499-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zandman-Goddard, G. (2002) Diffuse Alveolar Hemorrhage in Autoimmune Diseases. Israel Medical Association Journal, 4, 461-462.</mixed-citation></ref><ref id="hanspub.41499-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kornfield, Z.N., Horak, J., Gibbs, R.M., Weiss, S.J., Atluri, P., Augoustides, J.G.T., et al. (2015) CASE 2—2015: Extracorporeal Membrane Oxygenation as a Bridge to Clinical Recovery in Life-Threatening Autoimmune Acute Respiratory Distress Syndrome. Journal of Cardiothoracic &amp; Vascular Anesthesia, 29, 221-228.  
&lt;br&gt;https://doi.org/10.1053/j.jvca.2014.06.013</mixed-citation></ref><ref id="hanspub.41499-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Pathak, V., Kuhn, J., Gabriel, D., Barrow, J., Charles Jennette, J. and Henke, D.C. (2015) Use of Activated Factor VII in Patients with Diffuse Alveolar Hemorrhage: A 10 Years Institutional Experience. Lung, 193, 375-379.</mixed-citation></ref><ref id="hanspub.41499-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">林小鸿, 吴满辉, 吴海东. 系统性红斑狼疮并弥漫性肺泡出血17例临床分析[J]. 岭南急诊医学杂志, 2013. 18(4): 257-258.</mixed-citation></ref></ref-list></back></article>